Polycythemia Vera: Characteristic Signs, Progression, and Clinical Evaluation

Polycythemia vera (PV) is a chronic myeloproliferative neoplasm — a type of blood cancer that originates in the bone marrow. Unlike conditions caused by external factors, PV is driven by a genetic mutation, most commonly in the JAK2 gene, which causes an overproduction of blood cells. Because the condition develops slowly and its early symptoms can mimic everyday complaints, it is often discovered incidentally through routine bloodwork. Recognizing the full spectrum of signs and understanding how the disease evolves is essential for timely diagnosis and appropriate care.

This article is for informational purposes only and should not be considered medical advice. Please consult a qualified healthcare professional for personalized guidance and treatment.

Common Early Symptoms

In the early stages of polycythemia vera, many people experience symptoms that are easy to overlook or attribute to other causes. Fatigue is one of the most frequently reported complaints, often accompanied by a general sense of heaviness or sluggishness. Headaches, dizziness, and difficulty concentrating are also common, resulting from the increased viscosity of the blood and reduced oxygen efficiency. One hallmark early symptom is aquagenic pruritus — an intense itching sensation, particularly after a warm bath or shower — which occurs due to the release of histamine from elevated mast cell activity. Night sweats and unintentional weight loss may also appear as the disease progresses.

Skin, Vision, and Neurological Signs

As the red blood cell count rises, visible and sensory changes become more apparent. The skin may take on a reddish or ruddy appearance, especially in the face, hands, and feet — a condition referred to as plethora. Some individuals notice a bluish or purplish discoloration of the skin, known as cyanosis, particularly in the extremities when circulation is impaired. Vision disturbances, including blurred vision, double vision, or transient blind spots, can occur when blood flow to the eyes is affected. Neurological signs such as tingling sensations, numbness in the hands or feet, and episodes of dizziness or vertigo are not uncommon, reflecting the widespread impact of hyperviscosity on the nervous system.

Circulatory Problems and Blood Clot Risks

One of the most serious concerns in polycythemia vera is the significantly elevated risk of thrombosis — the formation of blood clots. Because the blood is thicker than normal, it flows more slowly and is prone to clotting in both arteries and veins. This can lead to deep vein thrombosis, pulmonary embolism, stroke, or heart attack. Erythromelalgia, a condition characterized by burning pain, redness, and warmth in the hands and feet, is another circulatory manifestation strongly associated with PV. Paradoxically, some patients also experience bleeding episodes, such as nosebleeds or gum bleeding, because the large number of platelets can impair normal clotting function.

Associated Findings: Enlarged Spleen and Lab Clues

Splenomegaly — an enlargement of the spleen — is a common physical finding in polycythemia vera. As the spleen attempts to compensate for the bone marrow’s overactivity, it begins producing blood cells itself, a process called extramedullary hematopoiesis. This can cause discomfort or a feeling of fullness in the upper left abdomen. On laboratory evaluation, PV is typically characterized by elevated hemoglobin and hematocrit levels, a high red blood cell mass, and often raised white blood cell and platelet counts. The presence of the JAK2 V617F mutation — found in over 95% of PV cases — is a key diagnostic marker. Elevated erythropoietin levels would suggest a secondary cause, while low or normal levels support a PV diagnosis. Bone marrow biopsy may be performed to confirm hypercellularity and rule out related conditions.

How Polycythemia Vera Is Clinically Evaluated

Diagnosis of polycythemia vera relies on a combination of clinical assessment, laboratory testing, and sometimes imaging. The World Health Organization (WHO) has established diagnostic criteria that include major markers such as elevated hemoglobin or hematocrit, the presence of the JAK2 mutation, and abnormal bone marrow findings. Minor criteria include subnormal serum erythropoietin levels. Physicians also use abdominal ultrasound to assess spleen size and monitor for hepatomegaly. Regular follow-up blood counts are essential not only for diagnosis but for tracking disease progression, as PV can transform over time into myelofibrosis or, less commonly, acute leukemia. Risk stratification — typically based on age and history of thrombosis — guides treatment planning.

Polycythemia vera is a condition that demands careful, ongoing clinical attention. From its subtle early symptoms to its more complex cardiovascular and hematological findings, the disease presents a layered picture that requires both awareness and thorough evaluation. With the right diagnostic approach, individuals living with PV can receive timely, evidence-based care that helps manage symptoms and reduce the risk of serious complications.